fmp012
Vaccineexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2012 (NCT01540474)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Plasmodium falciparumImmunity, active
Plasmodium falciparum immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- fmp012
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02174978 | Phase 1 | Aug 1, 2014 | GlaxoSmithKline, United States Agency for International Development, United States Army |
| NCT01540474 | Phase 1 | Feb 1, 2012 | Immune Design, United States Agency for International Development, United States Army |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| United States Agency for International Development | Government | 2 | 0 | 1 | 2012 |
| United States Army | Government | 2 | 2 | 1 | 2012 |
| GlaxoSmithKline | For profit | 1 | 0 | 1 | 2014 |
| Immune Design | For profit | 1 | 0 | 1 | 2012 |
4 organizations
Page 1 / 1